Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04084366 · ClinicalTrials.gov registry record · Phase 1
Phase 1/2 Study of OBI-999 in Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by OBI Pharma.
- Terminated
- Registry status
- Phase 1
- Development phase
- 44
- Enrollment target
NCT04084366 is a Phase 1 study that was terminated before completion, run by OBI Pharma. The registered enrollment target is 44 participants.
The verdict
NCT04084366, a Phase 1 study, was terminated before completion, sponsored by OBI Pharma.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 44 participants
- Enrollment target
Study Summary
The purpose of this study is to establish the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of OBI-999 as monotherapy, and to characterize the safety and preliminary clinical activity profile of the RP2D of OBI-999 in patients with advanced solid tumors.
Interventions
- DRUG OBI-999
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2019-11-25 |
| Est. Completion | 2023-10-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04084366
The ClinicalTrials.gov registry entry for NCT04084366 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is OBI Pharma, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which OBI-999 is the first listed.
NCT04084366 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04084366 about?
NCT04084366 is a clinical study titled "Phase 1/2 Study of OBI-999 in Patients With Advanced Solid Tumors". The purpose of this study is to establish the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of OBI-999 as monotherapy, and to characterize the safety and preliminary clinical activity profile of the RP2D of OBI-999 in patients with advanced solid tumors.
What is the current status of trial NCT04084366?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2019-11-25. Estimated completion is 2023-10-27.
What interventions are being tested in trial NCT04084366?
The interventions under investigation include: OBI-999 (DRUG).
Who is sponsoring clinical trial NCT04084366?
This trial is sponsored by OBI Pharma, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.